Treatment of pemphigus with rituximab.
- Author:
Jun LI
1
;
He-Yi ZHENG
;
Yue-Hua LIU
Author Information
1. Department of Dermatology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China. lijun35@hotmail.com
- Publication Type:Journal Article
- MeSH:
Antibodies, Monoclonal, Murine-Derived;
adverse effects;
therapeutic use;
Antigens, CD20;
immunology;
Humans;
Pemphigus;
therapy;
Rituximab
- From:
Acta Academiae Medicinae Sinicae
2009;31(1):107-110
- CountryChina
- Language:Chinese
-
Abstract:
Pemphigus is a life-threatening autoimmune blistering disease affecting the skin and mucosa. Patients with severe pemphigus require long-term treatment with corticosteroids and other immunosuppressive drugs, which can lead to serious adverse events. Rituximab, a monoclonal antibody directed against the CD20 antigen of B lymphocytes, has been demonstrated to be effective in recalcitrant and life-threatening pemphigus.
